[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-355748-105":59,"doc-detail-355748-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","copd-lung-cancer-comorbidity-mechanistic-insights-and-precision-oncology-implications","COPD - Lung Cancer Comorbidity: Mechanistic Insights and Precision Oncology Implications","","Chronic obstructive pulmonary disease (COPD) and lung cancer frequently coexist as a clinically consequential comorbidity with major implications for precision medicine. COPD acts as an independent driver of pulmonary carcinogenesis through persistent inflammation, genomic instability, epigenetic remodeling, and microbiome–immune dysregulation. COPD-associated lung cancer shows distinct molecular hallmarks that may shift therapy toward immune checkpoint blockade. The review integrates LDCT–spirometry, liquid biomarkers and AI radiomics for earlier detection, and outlines preventive and therapeutic strategies including statins, inhaled corticosteroids and microbiome modulation.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/copd-lung-cancer-comorbidity-mechanistic-insights-and-precision-oncology-implications/355748/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/copd-lung-cancer-comorbidity-mechanistic-insights-and-precision-oncology-implications/355748.png","ImageObject",300,407,{"name":92,"@type":93},"Cart","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-18","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is COPD considered more than a risk factor for lung cancer?","Question",{"text":112,"@type":113},"COPD is described as an independent driver of pulmonary carcinogenesis, mechanistically linked to persistent inflammation, genomic instability, and microbiome–immune dysregulation.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What molecular features distinguish COPD-associated lung cancer?",{"text":117,"@type":113},"The review highlights reduced EGFR mutation frequency, enrichment of LRP1B truncations, and elevated tumor mutational burden, which reprogram tumor immunogenicity and influence therapeutic responsiveness.",{"name":119,"@type":110,"acceptedAnswer":120},"How does the review propose improving diagnosis and prevention?",{"text":121,"@type":113},"It emphasizes integrating low-dose CT with spirometry, liquid biomarkers such as S100A12 and TLR4, and AI-enhanced radiomics, alongside microbiome-derived signatures for risk stratification and treatment personalization.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},355748,1790521131,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":36,"preview_page_count":19,"preview_urls":145},18829141979164,"https://eur-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","International Journal of Chronic Obstructive Pulmonary Disease  \nOpen Access Full Text Article REVIEW  \nCOPD–Lung Cancer Comorbidity: Mechanistic Insights and Precision Oncology Implications  \nYajuan He , Beili Liu, Wenjun Li, Xinyi Zhou, Hongyan Tao  \nDepartment of Pulmonary and Critical Care Medicine, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, 730000, People’s Republic of China  \nCorrespondence: Hongyan Tao, Department of Pulmonary and Critical Care Medicine, The Second Hospital & Clinical Medical School, Lanzhou University, 82 Cuiyingmen Street, Chengguan District, Lanzhou, 730000, People’s Republic of China, Email [1165463182@qq.com](1165463182@qq.com)  \n\n| Background: Chronic obstructive pulmonary disease (COPD) and lung cancer frequently coexist, constituting a clinically consequential comorbidity with major implications for precision medicine.\u003Cbr>Mechanistic Insights: Beyond shared environmental exposures such as tobacco smoke and air pollution, COPD has emerged as an independent driver of pulmonary carcinogenesis, mediated through persistent inflammation, genomic instability, epigenetic remodeling, and microbiome–immune dysregulation. Patients with COPD-associated lung cancer exhibit distinct molecular hallmarks, including reduced EGFR mutation frequency, enrichment of LRP1B truncations, and elevated tumor mutational burden, which collectively reprogram tumor immunogenicity and therapeutic responsiveness, favoring immune checkpoint blockade over targeted EGFR-directed therapy.\u003Cbr>Diagnostic and Preventive Strategies: Recent advances integrating low-dose CT (LDCT) with spirometry, liquid biomarkers (eg, S100A12, TLR4), and AI-enhanced radiomic algorithms have substantially improved early detection capabilities. In parallel, microbiome-derived signatures provide novel tools for risk stratification and treatment personalization.\u003Cbr>Therapeutic Implications: Preventive and therapeutic strategies, including statin therapy, inhaled corticosteroids, preoperative pulmonary optimization, and microbiome modulation, are emerging as promising approaches to intercept the COPD–lung cancer continuum and improve clinical outcomes.\u003Cbr>Conclusion: This review synthesizes current evidence spanning epidemiology, molecular pathogenesis, diagnostic innovations, and comorbidity-tailored interventions, culminating in a “comorbidity-centered precision management” framework. By bridging mechanistic discoveries with clinical implementation, this paradigm may contribute to reducing COPD–lung cancer mortality and could support the advancement of the global precision oncology agenda.\u003Cbr>Keywords: COPD–lung cancer comorbidity, precision medicine, immunotherapy, microbiome biomarkers, molecular pathogenesis, early detection |\n| --- |\n| Introduction\u003Cbr>Beyond serving as a risk factor, COPD is now recognized as an independent driver of pulmonary carcinogenesis, 1 mechanistically linked to persistent inflammation,2 genomic instability,3 and microbiome–immune dysregulation.4\u003Cbr>Chronic obstructive pulmonary disease (COPD) and lung cancer rank among the most prevalent and lethal respiratory disorders globally, together accounting for over three million deaths annually.5 Recent epidemiological analyses reveal a disproportionately high comorbidity prevalence, with 70–80% of lung cancer patients exhibiting concurrent COPD. Notably, individuals with emphysematous phenotypes face a 6.35-fold increased risk of developing lung cancer compared with non-COPD populations.5\u003Cbr>Despite these insights, critical knowledge gaps hinder optimal clinical management: (1) Diagnostic challenges—The significant symptomatic overlap between COPD and lung cancer contributes to underdiagnosis rates of 60–93% among lung cancer cohorts, delaying early detection.6,7 (2) Therapeutic paradox—COPD correlates with reduced efficacy of EGFR tyrosine kinase inhibitors (EGFR-TKIs) owing to lower EGFR mutation frequencies,8 yet paradoxically enhances |\n\n[https","cbCainY4kYm9ySlk","https://ap.wps.com/l/cbCainY4kYm9ySlk","pdf",3269318,16,"English","# Background\n## Mechanistic insights\n## Diagnostic and preventive strategies\n## Therapeutic implications\n## Conclusion\n# Introduction\n## Epidemiology and risk patterns\n## Diagnostic challenges\n## Therapeutic paradox\n## Mechanistic uncertainties\n# Transformative domains addressed in the review","[{\"question\":\"Why is COPD considered more than a risk factor for lung cancer?\",\"answer\":\"COPD is described as an independent driver of pulmonary carcinogenesis, mechanistically linked to persistent inflammation, genomic instability, and microbiome–immune dysregulation.\"},{\"question\":\"What molecular features distinguish COPD-associated lung cancer?\",\"answer\":\"The review highlights reduced EGFR mutation frequency, enrichment of LRP1B truncations, and elevated tumor mutational burden, which reprogram tumor immunogenicity and influence therapeutic responsiveness.\"},{\"question\":\"How does the review propose improving diagnosis and prevention?\",\"answer\":\"It emphasizes integrating low-dose CT with spirometry, liquid biomarkers such as S100A12 and TLR4, and AI-enhanced radiomics, alongside microbiome-derived signatures for risk stratification and treatment personalization.\"}]","COPD - Lung Cancer Comorbidity: Mechanistic Insights and Precision Oncology Implications | PDF",1790120781,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/89cc4911fb94069c7ae3698b2d06a182.webp",983,1272,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/423b9f9ce36d40eee33a61016f75b08b.webp",982,1270,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c859525a4ad89068f45fdc1f68ebef05.webp",981,1269,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/42f77c0135762c182c6e7d6834fa685c.webp",980,1268]